BIIB vs REGN
BIIB and REGN side by side — valuation & fundamentals (public data).
Key statistics
| Metric | BIIBBIOGEN INC. | REGNREGENERON PHARMACEUTICALS, INC. |
|---|---|---|
| Market cap | $37.49B | — |
| P/E (TTM) | 109.8 | 20.5 |
| P/B | 2.53 | — |
| P/S | 3.8x | — |
| Revenue | $10.30B(TTM) | $16.90B(TTM) |
| Revenue growth (YoY) | 2.2% | 1.0% |
| Net income | $347.60M(TTM) | $4.82B(TTM) |
| Earnings growth (YoY) | -20.8% | 2.1% |
| EPS, diluted | $2.31(TTM) | $45.24(TTM) |
| EBIT margin | 28.7% | 24.9% |
| ROE | 8.7% | 13.4% |
| ROIC | 12.3% | 9.2% |
| Piotroski F | 3/9 | — |
| 1y total return | +69.6% | +41.7% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: BIIB vs REGN
| Metric | BIIB | REGN |
|---|---|---|
| End value | $10.6K | $26.9K |
| Total return | +6.2% | +169.3% |
| CAGR | +0.6% | +10.1% |
| Volatility | 41.1% | 32.3% |
| Sharpe | 0.11 | 0.33 |
| Sortino | 0.18 | 0.49 |
| Max drawdown | -72.7% | -59.7% |
Based on 2600 common trading days, 2016-06-29 → 2026-10-30 · risk-free 4.16% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)